Our pipeline of drug candidates has been created and developed by our in-house R&D operation, Hutchison MediPharma, which was established in 2002.
Since then, we have assembled a large team of about 390 scientists and staff operating a fully-integrated drug discovery and development operation covering chemistry, biology, pharmacology, toxicology, chemistry and manufacturing controls for clinical and commercial supply, clinical and regulatory and other functions.
We have taken a chemistry-focused approach to develop highly selective small molecule tyrosine kinase inhibitors that are intended to have potentially global best-in-class efficacy and are deliberately engineered to improve drug exposure and reduce known class-related toxicities. Our current drug candidates may have the potential to be either global first-in-class therapies or be sufficiently differentiated to potentially be global best-in-class, next generation therapies with a superior profile compared to existing approved drugs that act against the relevant kinase targets.
We continue to leverage this platform to produce a stream of novel drug candidates.
For more information on recent developments, please review our recent Innovation news and the 2017 Annual Report.